Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Aim(s): Thus, we evaluated whether plasma CgA response to OT could predict the clinical response to SSAs.
Materials and methods: At diagnosis, 38 GEP-NET patients received octreotide 200 μg s.c., with plasma CgA determination at 0, 3 and 6 hours. Long-term SSA treatment was then given by monitoring clinical outcome.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Massironi S
To read the full abstract, please log into your ENETS Member account.